Anatomic outcomes are a critical measure of both disease activity and treatment success in neovascular retinal diseases. Attaining retinal dryness treating with anti-vascular endothelial growth factor (VEGF) therapy can be elusive and/or burdensome for a significant number of patients. Dual inhibition of angiopoietin 2 (Ang-2) and VEGF has demonstrated efficacy providing similar visual outcomes but enhanced reduction of retinal fluid for patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) with greater durability compared with anti-VEGF monotherapy. Whiteboard animations highlight the rationale and anatomic benefits of Ang-2 inhibition to illustrate the clinical application of dual Ang-2/VEGF inhibition in the case series of patients with nAMD, DME, and RVO with persistent fluid. Each case study will answer the questions, How dry am I? and, importantly, How dry can I get? and With how many injections?
- Provider:Paradigm Medical Communications, LLC
- Activity Link: https://ce.paradigmmc.com/a/YJHFWD
- Start Date: 2024-04-10 05:00:00
- End Date: 2024-04-10 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: Source: Genentech (Any division) - Amount: 169675.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all